论文部分内容阅读
目的:观察祛痰活血方辅助溶栓治疗急性心肌梗死(痰瘀互结型)的疗效。方法:将我院心内科收治符合纳入标准的急性心肌梗死(痰瘀互结型)68例,随机分为治疗组与对照组,每组各34例,对照组予溶栓等常规治疗;治疗组在对照组治疗的基础上予祛痰活血方治疗。治疗1月后,比较两组临床总疗效、临床相关生化指标(TC、TG、LDL、HDL、ET-1、NO)及并发症发生率、死亡率等。结果:疗程结束后,治疗组总有效率为82.3%,对照组为70.6%,治疗组并发症发生率与死亡率均低于治疗组,两组比较,差异均有统计学意义(P<0.05);治疗后,两组患者TC、TG、LDL、HDL、ET-1、NO等指标较前均有改善,然治疗组改善更明显,两组比较差异均有统计学意义(P<0.05)。结论:祛痰活血方辅助溶栓疗法可提高急性心肌梗死(痰瘀互结型)患者的临床疗效,改善心功能,同时还可降低并发症发生率及死亡率。
Objective: To observe the curative effect of Expelling Phlegm and Promoting Blood Circulation Adjuvant Thrombolysis on acute myocardial infarction (phlegm and blood stasis type). Methods: Sixty-eight patients with acute myocardial infarction (phlegm and blood stasis type) who met the inclusion criteria were randomly divided into treatment group and control group, with 34 cases in each group. The control group was given conventional therapy such as thrombolysis. In the control group on the basis of treatment expectorant Huoxue Fang treatment. After 1 month of treatment, the total clinical curative effect, clinically relevant biochemical indexes (TC, TG, LDL, HDL, ET-1, NO) and complication rates and mortality rates were compared. Results: After treatment, the total effective rate was 82.3% in the treatment group and 70.6% in the control group. The incidence of complications and mortality in the treatment group were lower than those in the treatment group. There was significant difference between the two groups (P <0.05 After treatment, the indexes of TC, TG, LDL, HDL, ET-1 and NO in the two groups improved compared with those in the former two groups, while the improvement in the treatment group was more obvious. There was significant difference between the two groups (P <0.05) . Conclusion: Expectorant and activating blood circulation adjuvant thrombolytic therapy can improve the clinical efficacy of acute myocardial infarction (phlegm and blood stasis type) patients, improve cardiac function, but also reduce the incidence of complications and mortality.